Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion

Abstract

Purpose To investigate whether interleukine-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) are related with macular oedema in patients with branch retinal vein occlusions (BRVOs). Design Retrospective case-control study. Participants Nineteen patients who had macular oedema due to BRVO and nine patients with non-ischaemic ocular diseases (control group). Methods Macular oedema was examined by optical coherence tomography. Both venous blood and vitreous samples were obtained at the time of vitreoretinal surgery. IL-8 and MCP-1 levels in vitreous fluid and plasma were determined with enzyme-linked immunosorbent assay kits. Variables were compared with the Mann-Whitney U-test, Wilcoxon's signed-ranked test, and the v 2 -test, when appropriate. To examine correlations, Spearman's rank-order correlation coefficients were calculated. Statistical significance was set at Po0.05. Results The vitreous fluid levels of IL-8 (median: 63.5 pg/ml) and MCP-1 (median: 1522.4 pg/ml) were significantly higher in the patients with BRVO than in the control group (median: 5.1 and 746.5 pg/ml respectively; Po0.001 and o0.001 respectively). Vitreous IL-8 and MCP-1 were significantly correlated in patients with BRVO (P ¼ 0.009). Conclusions Both IL-8 and MCP-1 were elevated in the vitreous fluid of patients with BRVO and macular oedema. Both chemokines may contribute to the pathogenesis of macular oedema in patients with BRVO.

Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion

“…The strong efficacy of anti-VEGF treatment indicates that VEGF plays an important role in the development of macular edema due to RVO. However, various cytokines, including interleukin-6 [2223] and interleukin-8 [24], can also be an effective treatment for macular edema in RVO. It is possible that the cases of macular edema in our study population refractory to intravitreal anti-VEGF injection involved pathological changes unrelated to VEGF.…”

Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion

“…It is possible that our study cohort had a more compromised ocular perfusion than eyes without ME recurrence following BRVO. These eyes may have also had higher levels of ME-inducing agents, including VEGF [26], interlukin-6 [26], and interlukin-8 [27]. …”

Proteins involved in focal adhesion signaling pathways are differentially regulated in experimental branch retinal vein occlusion

“…Studies on protein changes following BRVO have traditionally been conducted using ELISA kits to study samples from the aqueous humor and the vitreous body from patients with macular edema (Campochiaro et al, 2009;Fonollosa et al, 2010;Noma et al, 2012Noma et al, , 2008. The study of large-scale proteome changes at the retinal level following BRVO requires the use of an experimental animal model.…”

“…Studies conducted on aqueous and vitreous samples from patients with macular edema as a complication to BRVO have resulted in the identification of a small number of proteins that are thought to be involved in formation of edema in the macula (Fonollosa et al, 2010;Noma et al, 2005Noma et al, , 2012. However, the majority of patients with BRVO do not develop macular edema (Rogers et al, 2010) and protein changes at the retinal level following BRVO remain largely unstudied.…”